Company intelligence / Profile preview

SparX Group

Ownership: Private
Development stage: Other

Overview

SparX Group has initiated multiple Phase 1 trials for its lead bispecific antibodies and ADCs targeting solid tumors, including SPX‑101 against Claudin18.2 and SPX‑303, a first-in-class anti-LILRB2/PD-L1 bispecific antibody. The company is leveraging proprietary platforms to optimize therapeutic window and immune engagement in oncology indications.

Therapeutic areas: Oncology
Modalities: Bispecific antibodyAntibody-drug conjugateMonoclonal antibodySynthetic peptide (minor)
Industry: Biotech

Partnerships

Mitsubishi Tanabe Pharma America—collaboration on novel ADC program targeting immune cells across multiple tumor types

Beyond the preview

Go deeper on SparX Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SparX Group.

Explore the full profile